Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cytisinicline on Neural Substrates of Cigarette Cue-Reactivity
NCT06617312Phase 2Recruiting
- Sponsor
- University of California, Los Angeles
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Tobacco Use Disorder (TUD) comparing Cytisinicline with Placebo (2 arms). Primary endpoint: Blood-oxygen-level-dependent activation to cigarette cues during fMRI task. Started Dec 2024; status: recruiting.
02
Drugs
cytisinicline
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT06617312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06617312.